The first full day of the IPBC Global in San Francisco is now done and dusted. Here, IAM’s editorial team – Joff Wild, Richard Lloyd, Jack Ellis and Sara Jayne Clover – pick out a few of the highlights from the sessions and from the conversations…
The latest edition of IAM Strategy 300: The World’s Leading IP Strategists is now available online. As in previous years, it lists individuals that in-depth research has shown to possess world class skills in the development and roll-out of…
Boeing may have a world famous brand and have been a leader in the aerospace industry for almost 100 years, but it is not as well known when it comes to IP and the monetisation of its large portfolio. But having re-thought its IP strategy several…
Ford is ‘opening’ a portfolio of its patents relating to electric vehicle (EV) technology to “competitive automakers to accelerate industry-wide research and development of electrified vehicles,” according to a press release from the US company…
Orin Herskowitz is head of technology transfer at Columbia University, one of the most respected and successful university licensing operations in the United States. His role not only means that he is plugged into the steady stream of new technology…
One notable aspect of the debate over whether there is a need for further legislative reform of the US patent system is that almost without fail those who call for new laws do so on the basis that only by making it harder for all patent owners to…
In the last couple of years there have been several attempts to stymie privateering – the model by which operating companies sell patents to an NPE which then seeks to monetise them, usually through an assertion campaign. The original owner may…
Merck has become the latest foreign pharmaceutical innovator to notch a patent win in an Indian court. Last Friday, the country’s Supreme Court enjoined Glenmark Generics from selling new low-cost versions of diabetes drugs Januvia and Janumet …
The following is a brief extract from a letter which a national legislator sent to a member of the cabinet earlier this week: “I ask you to utilise federal law… to break the patents on these drugs to authorise third parties to manufacture or…
Yesterday this blog took a look at the huge difference in the amount of costs incurred by operating companies in the US as the result of NPE litigation put forward by Boston University professors James Bessen and Michael Meurer on the one hand, and…
In June 2012, James Bessen and Michael Meurer published their frequently-cited paper “The Direct Costs from NPE Disputes”, with its headline grabbing claim that US companies “accrued $29 billion of direct costs in 2011” as a result of NPE assertions…
On the sidelines of the INTA annual meeting in San Diego, IAM attended a seminar on the last year’s changes to trademark law in China. There was a nice bonus at the end, though, in the form of a discussion of patent litigation trends from Wan Hui Da…
As keen readers of this blog will know, we have subscribed to the idea that a period of consolidation among NPEs, and publicly traded IP companies in particular, is going to be one of the trends in the patent market over the next few years. In March…
The transcript of Qualcomm’s recent investor call to discuss its latest quarterly results is a must-read for anyone in the licensing business. The giant chipmaker remains a pretty good bellwether for the market and has faced recent challenges over…
There were over 250 attendees at a packed-to-the-rafters IPBC China, which took place this week at the Shangri-La Hotel in Haidian, Beijing. Delegates, mostly local IP professionals working inside major Chinese businesses, participated in a series…
